Founded in 2010, The Native Antigen Company has rapidly become one of the world’s leading suppliers of infectious disease reagents. Our portfolio of reagents continues to expand rapidly, and we are widely acknowledged to be a primary source of reagents and kits for the study of emerging diseases. In July of 2020, The Native Antigen Company was acquired by The LGC Group, a global leader in the life sciences sector, and will be part of the LGC Clinical Diagnostics Business Unit. Read more.
What do we do?
We’re a leading supplier of native and recombinant viral and bacterial antigens, antibodies and immunoassays, alongside bespoke custom and contract services.
Our infectious disease reagents are widely adopted by pharmaceutical, in vitro diagnostics and vaccine manufacturers, as well as leading academic groups in cutting-edge research, where correct folding and glycosylation of proteins is vital. We also offer our expertise on a contract basis to other sectors where highly purified proteins are required.
We are an ethical and sustainable organisation and are proud of our long-term relationships with our customers and partners.
VirtuE Expression System
The Native Antigen Company has developed a proprietary HEK293 mammalian expression system (VirtuE) for expression of recombinant proteins. Our VirtuE system is able to introduce proper protein folding and full post-translational modifications, which are essential for full biological and antigenic activity.
In addition to producing world-leading reagents for infectious disease, we believe we have a responsibility to our customers, our staff and to the planet to behave ethically and sustainably in running our business. We will always be open and honest in all of our communications with customers. We also strive to minimise our environmental footprint, exemplified by our use of 100% renewable energy, and recycled packaging wherever possible.